Figure 4.

Effect of mevalonate in combination with simvastatin on morphology, cell viability, and active caspase‐3 expression. (a) Photographs were taken 48 h after treatment with simvastatin (10 µM) or combination of simvastatin (10 µM) and mevalonate (2 mM). (b) Cell viability was measured 48 h after treatment with vehicle, 2 mM mevalonate (MA), 10 µM simvastatin (sim), and combination of mevalonate and simvastatin (sim + MA). (c) Western blot analysis for active caspase‐3 was performed in samples from head and neck squamous cell carcinoma cells which were treated with vehicle, 2 mM mevalonate (MA), 10 µM simvastatin (sim), or a combination of mevalonate and simvastatin (sim + MA) for 48 h.